Figure 1. Analysis schema.
T-T, tesamorelin responders at week 26 assigned to continue tesamorelin for an additional 26 weeks. T-P, tesamorelin responders at week 26 switched to placebo for 26 weeks.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.